Mayne Pharma on a high
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Mayne Pharma Group (MYX) looks poised to retest its record high after revealing that its interim result will be ahead of expectations.
The stocks staged its best one-day gain in 2½-months of 7.5% to 79 cents, and is just 3 cents shy of last November’s all-time high.
The generic drug supplier is expecting total revenue for the six-months to end December to range between $68 million and $71 million as underlying earnings before interest, tax, depreciation and amortisation (EBITDA) comes in at $18.6 million to $19.1 million.
The figures are comfortably ahead of the $61.1 million in sales and $17.1 million for EBITDA that the market was expecting.
The strong result is driven by recent acquisitions, new product launches, increasing market adoption of its drugs and the falling Australian dollar, which helps its translated earnings as the United States accounts for more than 60% of group sales.
Mayne, which is part of the Uncapped 100, is expected to post its half-year results on February 26.